| |
Control(30) |
MS(15)
(Short) |
MS(15)
(Long) |
Z |
P |
| Age |
39±11 |
36±8 |
39±9 |
|
|
| Dur of Disease (Months) |
|
16±10 |
124±48 |
|
|
| EDSS |
|
1.2±1 |
2.6±2 |
|
|
| MMSE |
|
27±2 |
26±3 |
|
|
| Frontal Latency(ms) |
|
|
|
|
|
| N100 |
105±18 |
106±8 |
109±13 |
0.254 |
0.77 |
| P200 |
173±18 |
182±29 |
183±22 |
1.364 |
0.26 |
| N200 |
225±23 |
244±45 |
250±30 |
3.460 |
0.038*** |
| P300 |
342±42 |
335±43 |
376±42 |
4.653 |
0.014*** |
| Central Latency(ms) |
|
|
|
|
|
| N100 |
105±18 |
107±9 |
111±18 |
0.744 |
0.48 |
| P200 |
173±18 |
184±27 |
181±19 |
1.343 |
0.27 |
| N200 |
225±23 |
236±45 |
250±33 |
2.688 |
0.07 |
| P300 |
345±37 |
332±43 |
378±38 |
5.041 |
0.010*** |
| Parietal Latency(ms) |
|
|
|
|
|
| N100 |
106±18 |
108±14 |
115±16 |
1.21 |
0.30 |
| P200 |
173±18 |
183±29 |
186±24 |
1.748 |
0.18 |
| N200 |
226±23 |
243±35 |
253±31 |
4.432 |
0.016*** |
| P300 |
342±32 |
337±42 |
390±39 |
9.121 |
0.000*** |
***PostHoc analysis of ANOVA comparisons revealed that the significant
differences (increases) in ERP’ latencies was present in between controls and in
patients with longer disease duration |
